Project on

A Review on Colon-Specific Drug Delivery Systems (CDDS)

PROJECT REPORT

[In the partial fulfillment of the requirements for the degree of Bachelor of Pharmacy]

Submitted To

The Department of Pharmacy,

Faculty of Allied Health Sciences,

Daffodil International University

Submitted By

Asma-UL-Husna

Student ID: 201-29-327

Department of Pharmacy,

Faculty of Allied Health Sciences,

Daffodil International University

…….....

April 2024

APPROVAL

This project paper, **"A Review on Colon-Specific Drug Delivery Systems (CDDS)",** submitted to the Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, has been accepted as satisfactory for the partial fulfillment of the requirements for the degree of Bachelor of Pharmacy and approved as to its style and contents.

BOARD OF EXAMINERS

……

Dr. Muniruddin Ahmed

Professor and Head,

Department of Pharmacy,

Faculty of Allied Health Sciences,

Daffodil International University

……	Internal Examiner 1
…….	Internal Examiner 2
……	External Examiner 3

DECLARATION

I hereby declare that this project report, **"A Review on Colon-Specific Drug Delivery Systems (CDDS)",** is done by me under the supervision of **Ms. Aklima Akter Assistant Professor,** Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University. I am declaring that this Project is my original work. I also declare that neither this project nor any part thereof has been submitted elsewhere for the award of Bachelor or any degree.

Supervised By



……

Ms. Aklima Akter

Assistant Professor

Department of Pharmacy

Faculty of Allied Health Sciences

Daffodil International University

Submitted By



……

Asma-UL-Husna

Student ID: 201-29-327

Department of Pharmacy

Faculty of Allied Health Sciences

Daffodil International University

ACKNOWLEDGEMENT

I might want to communicate my profound applause to the All-powerful Allah who has given me the capacity to finish my undertaking work and the chance to concentrate in this subject.

I'm a lot of thankful to my honorable project supervisor of **Ms. Aklima Akter Assistant Professor**, Department of Pharmacy, Daffodil International University for her brilliant direction and steady oversight just as for giving essential data in regards to the task and furthermore for her help in finishing the project.

I would like to express my humble regards to Dr. Muniruddin Ahmed, Professor and Head, Department of Pharmacy, Daffodil International University.

I also wish to offer my respect to all of the teachers of Pharmacy Department, Daffodil International University and thankful to other members for their excellent cooperation with us.

Finally, I would like to express my gratitude towards my parents and other family members for their kind cooperation and encouragement which helped me in completion of this project.

My Parents,

The persons who always encourage me in every sphere of my life.

My teacher,

The persons who guided me in this process and the committee who kept me on track.

Abstract

Colon-specific drug delivery systems (CDDS) have appeared as a talented possibility for the directed management of various gastrointestinal diseases and systemic conditions. This review aims to provide a comprehensive overview of CDDS, their design principles, advantages, challenges, and recent advancements. In this context, CDDS offer a solution by delivering therapeutic agents specifically to the colon, minimizing systemic exposure, reducing side effects, and enhancing therapeutic outcomes. This review delves into the various strategies employed in the development of CDDS, including pH-dependent systems, time-controlled release, and colonic prodrugs. It also discusses the formulation approaches, materials, and technologies that enable precise drug targeting to the colon. Mesalamine & Budesonide are the available drug for Colon specific drug delivery system. Additionally, this review explores the clinical relevance of CDDS, highlighting their potential in improving patient compliance, reducing dosing frequency, and enhancing the bioavailability of poorly soluble drugs. It also examines the challenges and limitations in the field, such as inter-individual variations in colon physiology, safety concerns, and regulatory issues. The role of personalized medicine and the potential impact of CDDS on the treatment of specific diseases are also discussed. CDDS come with limitations related to variability in transit times, precision, patient variability, and formulation challenges. However, further research is necessary to overcome existing challenges and ensure the safety and efficacy of these systems. This review attends as a respected reserve for researchers, clinicians, and pharmaceutical professionals seeking a deeper understanding of CDDS and their potential applications in modern healthcare.

Table of Contents

List of Tables

List of Figures

Chapter one
Introduction

1. Introduction

Pharmaceutical professionals have been paying close attention to colon-specific drug delivery systems (also known as CDDS) because of their potential to maximize the effectiveness of therapy and reduce adverse medication reactions. The main features and benefits of colon-specific drug delivery systems will be covered in this overview, along with certain difficulties and potential future developments (Vandamme et al., 2002). The specialized therapy of numerous colonic disorders, primarily inflammatory bowel disease, benefits from the location-specific administration of medications to lower portions of the GI tract. Other among possible uses of colonic delivery are chrono-therapy, prevention of colon cancer with nicotine treatment for addiction. It has also become more significant, not only for the distribution of medications for treating regional illnesses, in addition to a possible location for the systemic administration of curative peptides and proteins that Getting infused with the substance. When these distribution methods are combined once taken orally, let the medication exit through the delivery mechanism. The delivery mechanism enters the colon (John, 2003). These delayed activities are meant to boost the medicine's efficacy by highlighting the drug molecules where they are most required. Additionally, they seek to lessen the likelihood of any negative responses and issues with medication stabilization resulting from the drug's premature release in the stomach and small intestine, which are the top regions of the GIT. Lower quantities, fewer systemic side responses, and direct disease-site therapy would all be ensured by customized drug administration through the colon. In additional to restricted therapies, the colon can serve as a portal for the administration of drugs into the body's circulation (Bajpai, 2003). The success of a colon-specific drug delivery system (CDDS) depends on the medication's physico-chemical properties, the type of medication delivery system being utilized, any other factors that may impact the GI transit a period of time and the degree to which the drug interacts with the GI tract. Oral CDDS is essential to stop the drug from being released in the stomach and small intestine. The purpose of the approaches used in creating a CDDS is to delay the drug administration before the system hits the colon, albeit some strategies are more effective than others. A number of commercial preparations mention combining the more modern and traditional methods covered above (Kim H *et al*., 2012). Other among possible uses of colonic delivery are chrono-therapy, prevention of colon cancer with nicotine treatment for addiction. It has also become more significant, not only for the distribution

of medications for treating regional illnesses, in addition to a possible location for the systemic administration of curative peptides and proteins that Getting infused with the substance. When these distribution methods are combined once taken orally, let the medication exit through the delivery mechanism. The delivery mechanism enters the colon. It ought to be regarded as advantageous in the management of colon disorders. One location where local or systemically medication delivery may be accomplished is the colon (Hong, 2015). Colonic delivery compositions can also be used to transport pharmaceutical proteins and peptides, which are polar and/or vulnerable to mechanical and chemical breakdown in the upper GI tract and are significantly impacted by hepatic metabolism. Topical medications for inflammation bowel conditions including Crohn's disease or ulcerative colitis. Sulphasalazine and glucocorticoids are typically used to treat such inflammatory disorders



Figure 1: Physiology of human colon

Figure 1 describe physiological structure of human colon like appendix, rectum & anus (Agarwal, 2015)

1.1 Targeted drug delivery systems

Targeted drug delivery systems, often referred to as drug delivery vehicles or drug carriers, and are designed to improve the specificity and effectiveness of drug delivery to a particular site within the body while minimizing the exposure of healthy tissues to the drug. These systems are important in medicine because they can enhance the therapeutic effects of drugs, reduce side effects, and improve patient compliance. Here are some key aspects of targeted drug delivery systems:

Targeting Mechanisms: These systems use various targeting mechanisms to ensure the drug is delivered to the desired site. There are several types of targeting mechanisms, including passive and active targeting (Barik *et al.*, 2004). It ought to be regarded as advantageous in the management of colon disorders. One location where local or systemically medication delivery may be accomplished is the colon (Hong, 2015). Colonic delivery compositions can also be used to transport pharmaceutical proteins and peptides, which are polar and/or vulnerable to mechanical and chemical breakdown in the upper GI tract and are significantly impacted by hepatic metabolism. Topical treatments for inflammatory bowel diseases, such as ulcerative colitis or Crohn's disease. Glucocorticoids and Sulphasalazine are commonly used to treat such inflammatory diseases.

Focusing by passive means: This method depends on the distinct physiological features of the intended target. For instance, drug carriers can concentrate more in the tumor tissue due to the increased permeability and retention (EPR) impact of blood arteries that are frequently leaky in tumors.

Using ligands on the outermost layer of the drug carrier, including peptides or antibodies, is known to be active aiming. According to Beckert et al. (2005), these ligands have the ability to bind selectively to receptors on the target region, guaranteeing more accurate drug delivery.

Different Drug Carriers: Liposomes, nanoparticles, micelles, and other carriers are among the many that can be utilized to carry drugs. These carriers enhance the drug's delivery to the intended place, prevent it from degrading, and regulate its dissolution.

Controlled Drug Release: Many targeted drug delivery systems provide controlled release of the drug over time. This allows for a sustained therapeutic effect and reduces the need for frequent dosing (Belofsky *et al.*, 2005).

Reduced Side Effects: By delivering the drug directly to the target tissue, these systems minimize exposure to healthy tissues. This can reduce the side effects associated with some drugs.

Applications: Targeted drug delivery is widely used in various medical fields, including oncology (for cancer treatment), immunology (for autoimmune diseases), and more. It can also be used for the treatment of various conditions, such as diabetes, cardiovascular diseases, and neurodegenerative disorders.

Challenges: Developing effective targeted drug delivery systems can be challenging. These challenges include ensuring the carrier's stability, avoiding the immune system's clearance, and maintaining the carrier's integrity until it reaches the target site.

Examples: Some well-known examples of targeted drug delivery systems include Doxil (liposomal doxorubicin) for cancer treatment and Herceptin (trastuzumab) for breast cancer, which is an antibody-based therapy targeting HER2-positive cancer cells.

Overall, targeted drug delivery systems represent a promising area of research and development in medicine, with the potential to improve the efficacy and safety of various therapies. These systems are continually evolving, and ongoing research is focused on optimizing their design and application (Hema, 2017).

1.2 Benefits of colon specific drug delivery system

To guarantee less dosage, less systemic adverse reactions, and immediate intervention at the site of the illness. To extend the duration of medication distribution, colon-specific composition may also be utilized. It ought to be regarded as advantageous in the management of colon disorders. One location where local or systemically medication delivery may be accomplished is the colon (Hong, 2015). Colonic delivery compositions can also be used to transport pharmaceutical proteins and peptides, which are polar and/or vulnerable to mechanical and chemical breakdown in the upper GI tract and are significantly impacted by hepatic metabolism. Topical treatments for inflammatory bowel diseases, such as ulcerative colitis or Crohn's disease. Glucocorticoids and

Sulphasalazine are commonly used to treat such inflammatory diseases. Many other significant illnesses, including colorectal cancer, would be treated more effectively if drugs were targeted to the colon (Modasiya, 2012). Pharmaceutical proteins and peptides, which are polar and/or susceptible to chemical and mechanical degradation in the upper GI tract and are highly influenced by hepatic metabolism, can also be transported via colonic administration formulations (Iqbal et al., 2015). Some well-known examples of targeted drug delivery systems include Doxil (liposomal doxorubicin) for cancer treatment and Herceptin (trastuzumab) for breast cancer, which is an antibody-based therapy targeting HER2-positive cancer cells.

1.3 Drug criteria for a colon specific delivery

The subsequent physico-chemical/therapeutic requirements should be met by drugs intended for integration into a colon-specific route of administration. These drugs should initially appear as local therapies in the colon in order to cure intestinal problems. Both peptide drugs, such as amylin, and non-peptide drugs, such as oxyprenolol, have these side effects. Secondly, it's likely that the upper gastrointestinal tract doesn't absorb these drugs in the same way it should. Pharmaceutical proteins and peptides, whose structure is polar and/or susceptible to chemical and mechanical degradation in the upper GI tract and are greatly influenced by hepatic metabolism, can also be transported using colonic delivery formulations. Antianginal medications like isosorbide denigrate fall within this category. Medications such as 5-flurouracil and capecitabine, which are utilized for managing colon or rectal malignancies, are also excellent choices for CDDS (Agarwal *et al.*, 2015). The residual requirements encompass a high probability of first-pass metabolism (e.g., corticosteroids) or drug destruction in the stomach due to the acidic environment or enzymatic (e.g., peptide medicines such insulin and gonadorelin) (Kaushik *et al*., 2013).

1.4 Structural parameter and function of colon

An essential component of the human gastrointestinal system is the colon, sometimes referred to as the big intestine. It is essential for the creation and storing of feces prior to to expulsion, as well as the absorption of water and electrolytes (Beckert et al., 2005). Here are some vital details regarding the human colon:

Location: The colon is located in the abdominal cavity and is part of the gastrointestinal tract. It follows the small intestine and precedes the rectum and anus.

Structure: The colon is a tube-shaped organ that is divided into several segments:

Ascending Colon: This is the first part of the colon, located on the right side of the abdomen.

Transverse Colon: It runs horizontally across the upper abdomen.

Descending Colon: This portion descends down the left side of the abdomen.

Sigmoid Colon: The sigmoid colon is an S-shaped section that connects the descending colon to the rectum (Lodhi, 2014).

- **Functions:**

Absorption of Water: The primary function of the colon is to absorb water and electrolytes from the indigestible residue of food passing through from the small intestine. This process converts the liquid chyme into a semisolid fecal material (Beloqui *et al.*, 2014).

Fermentation: Beneficial bacteria in the colon help ferment undigested carbohydrates and produce vitamins like vitamin K and some B vitamins.

Storage: The colon stores fecal material until it is ready for elimination, preventing the need for constant defecation.

Elimination: The colon is the site of the final phase of digestion, where bacteria, waste materials, and undigested food combine to generate feces. Eventually, throughout a bowel movement, feces are ejected from the body through the rectum and anus (Goyal, 2016).

1.5 Limitation of colonic drug delivery

Colonic drug delivery, also known as colonic drug targeting or colonic drug release, is a method of delivering medications to the colon (large intestine) for the treatment of various diseases and conditions. While this approach offers several advantages, it also has some limitations. Here are some of the limitations of colonic drug delivery (Das *et al*., 2010):

Variability in transit time: The transit time through the gastrointestinal tract can vary significantly among individuals, making it challenging to ensure that the drug reaches the colon at the intended time. Factors such as age, diet, disease conditions, and individual variability can affect transit time (Leuva *et al.*, 2012).

Unpredictable drug release: Achieving precise and predictable drug release in the colon can be difficult. Variability in the physiological conditions of the colon, such as pH, microbiota, and motility, can affect drug release patterns.

Incomplete drug release: In some cases, the drug may not be completely released in the colon, leading to reduced therapeutic efficacy. Incomplete release can result from variations in pH, drug formulation, and other factors (Kumar *et al.*, 2010).

Potential side effects: Colonic drug delivery systems may cause side effects such as diarrhea or gastrointestinal discomfort due to the presence of drugs in the colon. These side effects can be bothersome to patients and affect compliance.

Limited applicability: Colonic drug delivery is primarily used for conditions specific to the colon, such as inflammatory bowel diseases (e.g., Crohn's disease, ulcerative colitis) or colorectal cancer. It may not be suitable for treating systemic diseases or conditions affecting other parts of the body (Philip and Philip, 2010).

Patient compliance: Ensuring patient compliance with colonic drug delivery systems can be challenging, as patients need to take medications at specific times or under particular conditions, such as on an empty stomach. This can be inconvenient for some individuals.

Development and manufacturing challenges: Developing colonic drug delivery systems can be complex, and manufacturing consistency is crucial to ensuring drug release at the desired location and time. This can increase development costs and limit the availability of such medications.

Limited availability of approved products: There are relatively few approved colonic drug delivery products on the market. This limitation stems from the challenges associated with development, clinical testing, and regulatory approval.

Safety concerns: Some colonic drug delivery systems may pose safety concerns, as they can interact with the colonic microbiota and potentially affect the balance of gut bacteria. This could have implications for overall gut health.

Cost considerations: Colonic drug delivery systems can be more expensive than traditional oral drug formulations, which may limit their accessibility to some patients.

Despite these limitations, colonic drug delivery remains an important area of research and development, particularly for conditions that require localized therapy in the colon. Researchers continue to explore new strategies and technologies to overcome these challenges and improve the effectiveness of colonic drug delivery (Kumar, 2008).

1.6 Benefits of colon specific drug delivery system

Colon targeting drug delivery systems offer several benefits, particularly in the context of treating conditions and diseases affecting the colon. These systems are designed to deliver drugs specifically to the colon region, and their advantages include (Malayandi *et al*., 2014):

Localized drug delivery: Colon targeting drug delivery systems enable the precise and localized delivery of drugs to the colon, reducing systemic exposure. This can help minimize side effects and improve the therapeutic effect of the drug.

Enhanced efficacy: Many diseases, such as inflammatory bowel disease (IBD), Crohn's disease, and colon cancer, primarily affect the colon. Targeted drug delivery allows for higher drug concentrations at the site of action, increasing the drug's effectiveness in treating these conditions (Coupe *et al.*, 2020).

Reduced side effects: By minimizing drug exposure to other parts of the body, colon targeting drug systems can reduce systemic side effects that might occur with conventional drug delivery methods.

Improved patient compliance: Colon-targeted drug delivery can help maintain a consistent drug release over an extended period, reducing the frequency of dosing. This convenience can improve patient adherence to treatment regimens.

Protection of sensitive drugs: Some drugs are sensitive to the acidic environment of the stomach or the enzymes in the small intestine. Colon-targeted delivery systems can protect these drugs from degradation until they reach the colon, where they can be absorbed or act on the target.

Chronotherapy: Some diseases, like IBD, exhibit diurnal variations in symptoms. Colon-targeted drug systems can be designed to release the drug at specific times of the day to match the disease's circadian rhythm, optimizing treatment efficacy (Dressman *et al*., 2019).

Prolonged release: Colonic drug delivery systems can provide controlled and sustained release of medications over an extended period, maintaining therapeutic drug levels and reducing the need for frequent dosing.

Improved drug bioavailability: Certain drugs may have poor absorption in the upper gastrointestinal tract, but colon-targeted delivery can enhance their bioavailability by delivering them directly to the colon (Ibekwe *et al.,* 2008).

Minimized first-pass metabolism: For drugs that undergo significant first-pass metabolism in the liver, colon targeting can help bypass this process, allowing more of the drug to reach the colon intact.

Reduced healthcare costs: Enhanced drug delivery systems that improve the efficacy of colon-specific therapies can lead to better disease management, potentially reducing hospitalization and overall healthcare costs.

It's important to note that the effectiveness of colon targeting drug delivery systems depends on the specific formulation, patient factors, and the disease or condition being treated. The development and application of such systems continue to advance, offering promising prospects for more efficient and targeted drug therapies in the future. (Iqbal *et al*., 2015).

1.7 Diseases of colon

The colon, sometimes referred to as the large intestine, can be affected by a number of colonic illnesses. Among these are a few of these:

One of among the most prevalent types of cancer is colorectal cancer. If treatment is not received, it may develop into malignant polyps in the colon or rectum (Rubinstein, 2013).

IBD stands for inflammatory bowel disease, which includes diseases like Crohn's disease and ulcerative colitis. These are long-term inflammatory diseases that can impact the colon and present with indications like diarrhea, weight loss, and abdominal pain.

The inflammation or infection of tiny pouches (diverticula) that can occur in the colon is known as diverticulitis. Alteration in bowel habits, fever, and abdominal pain are possible outcomes.

Irritable bowel syndrome (IBS): IBS is a functional gastrointestinal disorder characterized by symptoms such as abdominal pain, bloating, and changes in bowel habits. It doesn't cause physical damage to the colon but can be quite uncomfortable (Hebden *et al.,* 2000).

Colorectal polyps: These are abnormal growths on the inner lining of the colon. While most polyps are not cancerous, some can develop into colorectal cancer over time.

Ischemic colitis: This condition occurs when there is reduced blood flow to the colon, leading to damage to the colonic tissue. Symptoms can include abdominal pain and diarrhea (Rana *et al*., 2013).

Microscopic colitis: This is a less common form of colitis, where inflammation occurs in the colon but is only visible under a microscope. It can cause chronic diarrhea.

Infectious colitis: Colonic infections, often caused by bacteria, parasites, or viruses, can lead to symptoms like diarrhea, abdominal pain, and fever.

Hereditary colorectal syndromes: Conditions like familial adenomatous polyposis (FAP) and Lynch syndrome are genetic disorders that increase the risk of colorectal cancer (Stubbs *et al.,* 2013).

Colonic ischemia: This is a condition where the blood supply to the colon is compromised, often due to vascular problems. It can lead to tissue damage and abdominal pain.

Radiation proctitis: This is an inflammation of the rectum that can occur as a side effect of radiation therapy for conditions like cancer.

These are some of the colonic diseases and conditions that can affect the large intestine. If you suspect you have a colonic disease or are experiencing symptoms related to the colon, it's essential to seek medical advice and evaluation from a healthcare professional. The treatment and management of these conditions can vary significantly, so a proper diagnosis is crucial (Scheppach, 2014).



Figure 2: Strategic approaches for colon targeted drug delivery

Figure 2 represent schematic process of targeted drug delivery system of colon (Hema, 2017)

1.8 Future prospects of targeted drug delivery systems

Focused medication delivery systems offer bright future prospects since they have the power to significantly enhance patient care and transform the medical industry. In the future of targeted drug delivery systems, the following significant trends and advancements should be anticipated:

Personalized medicine: Advances in genomics and proteomics are enabling the development of personalized drug delivery systems. Patients can have treatments tailored to their unique genetic makeup and disease characteristics, resulting in more effective and less toxic therapies.

Nanotechnology: Nanoparticles and Nano carriers are becoming increasingly important in drug delivery. These tiny structures can be engineered to target specific cells or tissues, improving drug efficiency and reducing side effects.

Biological targeting: Advances in biotechnology and molecular biology are leading to the development of biological targeting methods. Antibodies, peptides, and other biomolecules can be used to specifically target diseased cells, increasing the precision of drug delivery.

Smart drug delivery: Future systems will likely incorporate smart technologies, such as microchips, sensors, and remote control mechanisms, to regulate drug release in real-time. These systems can respond to changes in the patient's condition and adjust drug dosages accordingly.

Combination therapies: Targeted drug delivery systems will enable the simultaneous delivery of multiple drugs to enhance therapeutic outcomes. This approach is particularly valuable in the treatment of complex diseases like cancer and chronic conditions.

Improved drug formulations: Ongoing research in pharmaceutical sciences will result in the development of more stable and bioavailable drug formulations, ensuring that the right amount of the drug reaches its target.

Noninvasive delivery: Future targeted delivery systems may largely eliminate the need for invasive procedures, such as injections or surgical implantation, by utilizing less invasive methods like transdermal patches or inhalation devices.

Advanced imaging and diagnostics: Targeted drug delivery will benefit from advanced imaging and diagnostic techniques, allowing for precise identification of drug targets and monitoring of treatment effectiveness in real-time.

Regulatory and ethical considerations: As these technologies evolve, there will be a need for updated regulatory frameworks to ensure patient safety. Ethical considerations regarding the use of highly personalized drug delivery systems and data privacy will also be important.

Global accessibility: The challenge will be to make these advanced drug delivery systems accessible and affordable worldwide. Efforts will be made to ensure that breakthroughs in targeted drug delivery benefit a broad range of patients, not just those in high-income countries (Vandamme, 2002).

Research collaborations: Interdisciplinary collaborations between researchers in medicine, engineering, and biology will continue to drive innovation in targeted drug delivery. Cross-disciplinary research will be key to overcoming complex challenges.

Environmental impact: There will be a growing focus on ensuring that drug delivery systems are environmentally friendly and sustainable, considering the disposal of drug carriers and their impact on ecosystems.

Overall, the future of targeted drug delivery systems is poised to bring more effective, personalized, and efficient treatments to patients while reducing side effects and improving overall healthcare outcomes. However, as with any emerging technology, it will be important to address the associated challenges and ethical considerations as these systems become more prevalent in medical practice (Vassallo *et al.*, 2019).

Chapter two

Purpose of the study

2. Aim of the study

A review on colon-specific drug delivery systems serves several important purposes in the field of pharmaceutical research and development. These reviews are critical for advancing our understanding of drug delivery technologies and their applications in targeting the colon. Here are some key purposes of conducting a review on colon-specific drug delivery systems:

Knowledge synthesis: Review articles compile and summarize existing research and knowledge on colon-specific drug delivery systems. They provide a comprehensive overview of the current state of the field, including various approaches, technologies, and advancements.

Identifying trends: Such reviews help identify emerging trends and breakthroughs in colon-specific drug delivery. Researchers and pharmaceutical companies can use this information to stay updated on the latest developments and adjust their research priorities accordingly.

Assessment of effectiveness: Review articles often evaluate the effectiveness of different drug delivery systems designed for colon-specific targeting. They assess the advantages and limitations of various approaches, enabling researchers to make informed decisions about which systems to pursue or modify.

Comparative analysis: These reviews frequently compare different colon-specific drug delivery systems in terms of their performance, drug release profiles, biocompatibility, and patient acceptability. Such comparisons help researchers and clinicians select the most suitable approach for a specific drug or medical condition.

Innovation and improvement: By examining the shortcomings of existing colon-specific drug delivery systems, review articles can stimulate innovation. Researchers may identify gaps in knowledge or areas where further research is needed to enhance drug delivery efficiency and patient outcomes.

Clinical relevance: Reviews often discuss the clinical relevance of colon-specific drug delivery systems, including their potential applications in the treatment of various diseases such as inflammatory bowel disease, colorectal cancer, and irritable bowel syndrome. This information is valuable for clinicians and healthcare professionals.

Safety and biocompatibility: Safety is a crucial concern in drug delivery. Review articles may delve into the safety and biocompatibility aspects of different colon-specific delivery systems, highlighting any potential risks or challenges.

Regulatory considerations: They can provide insights into the regulatory aspects of developing and approving colon-specific drug delivery systems, helping researchers and companies navigate the complex regulatory landscape.

Future directions: Reviews often conclude with a discussion of future research directions and challenges in the field. This can guide researchers in planning their studies and grant proposals.

In summary, a review on colon-specific drug delivery systems plays a crucial role in advancing pharmaceutical research, improving drug delivery technologies, and enhancing patient care by providing a comprehensive understanding of the current state of the field and guiding future developments.

Chapter three

Methodology

3. Methodology

Search for peer-reviewed journal articles, books, conference proceedings, and regulatory guidelines related to colon-specific drug delivery systems. Reputable databases have been expenditure like PubMed, Scopus, or Google Scholar to find relevant publications.

- Work on this project was initiated in December 2023.
- Every effort has been made to gather as much information as possible using the following search terms: "Colon treatment," "Colon drug delivery system," "Colon drug specific delivery," and "Colon drug system in human." These terms were checked for potential use of academic bibliographic databases, web-based search engines, PubMed, Research Gate, Google scholar, and Medline.
- A literature analysis leads the inspection; about 40 publications are examined for this evaluation.
- Making an effort to compile all information from 2013 to 2023 and every work completed in Microsoft Word to streamline the procedure.
- After reading each produced assessment paper, it became more scholarly. Finally, a summary of all the proof gathered has been provided.

Chapter four
Literature Review

4. Colon Targeted Drug Delivery System: A Review on Current Approaches

The colon, which is the last segment of the gastrointestinal tract, has received attention as a possible delivery target for peptides and other new medicinal medicines. By delivering drugs both topically and systemically, the colon focused drug delivery system (CDDS) holds great promise for treating inflammatory bowel conditions like ulcerative colitis, Crohn's disease, colon cancer, and amobebiasis. This paper reviews a thorough investigation into colon illness, colon disease diagnosis, colon anatomy, factors influencing drug absorption, and various colon methods, such as a few modern colon addresses including the Pulsinicap framework, Port structure, probiotic strategy, chronotropic system, colon-pred system, and enterion capsule technology. Muliparticulate technology and a few earlier research on colon medication delivery with an assessment technique for colon drug administration targeted to particular locations (Lodhi, 2014).

4.1 Strategic Approaches for Colon Targeted Drug Delivery: An Overview of Recent Advancements

Colon-specific drug delivery systems have garnered significant attention as potential delivery methods for local therapy of colonic diseases with fewer systemic adverse reactions, as well as to enhance oral administration of various therapies prone to acidic and enzymatic decomposition in the upper gastrointestinal tract. The global pharmaceutical market for biologics has grown in the last few years due to the demand for a more patient-friendly drug administration system, highlighting the importance of colonic drug delivery as a noninvasive way to distribute macromolecules. Colon-targeted drug delivery systems for biomolecules can provide therapeutic benefits like improved patient compliance and lower costs, whilst being painless and self-administrable. Therefore, a range of strategies have been studied to provide more efficient colonic drug administration for local or universal therapeutic advantages. These strategies include pH-dependent frameworks, enzyme-triggered infrastructure, receptor-mediated systems, and magnetically-driven structures. With an emphasis on compositional the internet, this paper discusses recent advancements in several techniques for developing colon-targeted drug delivery systems and their therapeutic applications (Mahar, 2014).

4.3 Colon-Targeted Oral Drug Delivery Systems: Design Trends and Approaches

Colon-specific drug delivery systems, or CDDS, are appropriate for the treatment of a number of local ailments, such as ulcerative colitis, Crohn's disease, irritable bowel syndrome, chronic pancreatitis, and colonic cancer. Moreover, a number of drugs aimed at treating conditions other than colonic disorders may be systemically ingested through the colon. Medications including proteins and peptides, although have been demonstrated to degrade at very high pH, can be absorbed chronically by the colonic mucosa if administered to the colon intact. For the medication to have a positive therapeutic effect, the colon must be specifically targeted using the method of administration. Several compositional approaches have been studied to develop drug delivery systems targeted at the colon. These tactics use formulation chemicals that interact with one or more aspects of gastrointestinal (GI) physiology, such as pH fluctuations in the GI system, the presence of colonic bacteria, and catalysts, to achieve colon aiming for. The limitations of CDDS are discussed in this article along with the factors influencing colonic bioavailability and colon-specific medication delivery. The paper also provides a thorough examination of the various formulation methods and equipment that are currently being used for CDDS investigation, both conventional and relatively more modern (Duga, 2018).

Chapter five

Results & Discussion

5. Available Drug for Colon Specific Drug Delivery Systems (CDDS)

With the use of colon-specific drug delivery systems (CDDS), patients with illnesses like Crohn's disease, ulcerative colitis, and inflammatory bowel disease (IBD) can receive tailored treatments. Such structures are frequently employed to reduce systemic adverse effects and raise therapy effectiveness. Prodrugs, pH-sensitive polymers, and time-controlled releasing systems are a few of the strategies that have been developed for colon-specific drug delivery (Belofsky et al., 2014). The particular health problem and the intended therapy outcomes determine the drug and delivery method selection. Several medications and combinations have been created for colon-specific drug delivery as of my latest knowledge update in September 2021, although the accessibility of these medications may differ by location and may have changed subsequently then.

Some commonly used drugs and drug delivery systems for the colon include:

Mesalamine (5-ASA): Mesalamine is often used for the treatment of mild to moderate IBD, including ulcerative colitis. Various formulations, such as delayed-release tablets, capsules, enemas, and suppositories, are designed to deliver the drug to the colon (Bharadwaj *et al.,* 2021).

Budesonide: Budesonide is a corticosteroid used for the treatment of Crohn's disease. Controlled-release formulations can help target delivery to the colon.

Azathioprine and Mercaptopurine: These immunosuppressant drugs are used in the treatment of IBD. They may be administered orally in conventional or delayed-release forms (Chandra *et al.,* 2012).

Beclomethasone dipropionate: Another corticosteroid used for the treatment of Crohn's disease, available in controlled-release formulations.

Antibiotics: Antibiotics like Vancomycin may be used in the treatment of specific infections related to the colon. These are often administered orally.

Biologic agents: Biologic medications such as infliximab (Remicade) and adalimumab (Humira) are used to treat IBD. These drugs are administered via injection and affect the immune system.

Novel drug delivery systems: Several novel colon-specific drug delivery systems have been developed, including pH-sensitive polymers, microbially triggered systems, and time-controlled release formulations. These systems can be used to deliver a variety of drugs to the colon (Chopade *et al*., 2012).

5.2 Factor influencing colon specific drug delivery and colonic bioavailability

Many factors can affect the development of a colon-specific drug delivery system (CDDS) and the colonic accessibility of the drugs. Following is a brief explanation of some of these factors. (Dhami *et al.*, 2018).

5.2.1 Anatomical/Physiological factors

The rectum is a small distal portion of the 1.5 m long human large intestine, which forms the colon (ascending, transverse, and descending). The colon has a lumen coated with secretions and measures 2-3 inches in diameter. Compared to other parts of the gastrointestinal tract (GIT), the colon's physiology is very different (Table II). Additionally, there are differences in the physiological and physical characteristics of the colonic contents in the ascending, transverse, descending, and sigmoidal colons. Furthermore, food and dose forms flow differently throughout the colon, which could be problematic for the creation of colonic medication methods of administration (Glasier, 2012). The GIT's fluctuating pH is additional physiological element that influences colonic medication administration and absorption. Human illness states, fed and fasted stages, sexes, and ages have all been found to exhibit significant intra- and inter-subject heterogeneity in the pH of the GIT. The effectiveness of CDDS is additionally affected by parameters such the amount and viscosity of colonic fluids, the existence of microbial enzymes, and the subsequent colonic metabolism (Newman *et al.*, 2016).

5.2.2 Intestinal colonic transit time

The effectiveness of CDDS and the colonic accessibility of medications are significantly influenced by the intestinal-colonic transit time. Conditions related to colonic illnesses, including UC and CD, also affect transit times. Colic times in patients with UC have been shown to be less than those in healthy persons (~24 h versus ~52 h). In a similar vein, Rana et al. demonstrated that orocecal transit time was prolonged in IBD patients. The kind of dosage form, the timing of treatment, and the existence or omission of food all affect how dose forms move. The impact of

dawn and dusk on the motility of dosage forms in the colon was investigated by Stubbs et al (Patil, 2014). According to the findings, colonic transit was postponed throughout sleep, and bigger dose forms like capsules transformed more quickly than lower dosage forms like dispersed particles.

5.2.3 Colonic fluid volume

The typical daily intake of humans is 1.5 kg, primarily composed of lipids, carbohydrates, and uncooked proteins. These food elements may serve as antecedents to the microbial enzymes found in the colon. The colon's great ability for water absorption allows it to absorb about 90% of the water that enters it. Colic fluid is believed to have a volume of between 1 and 44 ml, on average. This low volume of intestinal fluids may affect the local bioavailability of pharmaceuticals and makes it more difficult for medications to dissolve within dose forms (Reynolds *et al*., 2002).

5.2.4 Viscosity of colonic luminal contents

The colonic luminal contents have more viscosity than the upper GIT components because of their greater potential to absorb water, which makes it more difficult for CDDS to dissolve. Additionally, as the substances go from the ascending colon to the descending colon, their viscosity gradually rises, which inhibits the ingestion of drugs via the mucosa. Viscosity affects how well a medication penetrates the colon's disease-causing germs. It has been demonstrated that the viscosity of the colonic material affects the motility of bacteria within the colon (Shah, 2015).

5.2.5 Colonic pH

The colonic luminal contents have more viscosity than the upper GIT components because of their greater potential for absorption water, which makes it more difficult for CDDS to dissolve. Additionally, as the substances go from the colon that ascends to the descending colon, their viscosity gradually rises, which inhibits the ingestion of drugs via the mucosa. Viscosity affects how well a medication penetrates the colon's disease-causing germs. It has been demonstrated that the viscosity of the colonic material affects the motility of bacteria within the colon (Bharadwaj *et al.,* 2021). Colic pH is known to be influenced by conditions related to gastrointestinal diseases, including ulcerative colitis. By affecting the solubility of medications in the colonic fluid, the pH of the colon influences the pharmacokinetic and pharmacodynamic behavior of a CDDS. Furthermore, the impact of colonic pH on drug release is amplified if one or more of the dosage

form's components such as a pH-sensitive coated membrane—are pH-sensitive. (Chandra *et al.*, 2012).

5.2.6 Colonic enzymes and metabolism

More than 400 distinct species of anaerobic and aerobic bacteria, such as Clostridium species and Escherichia coli, have been identified in the colon. Numerous hydrolytic and reduction enzymes that metabolize are present in these bacteria. The metabolism of xenobiotics (drugs, for example) and other biomolecules (bile acid, for example), the deactivation of toxic metabolites, and the biosynthesis of carbohydrates and proteins are all catalyzed by the colonic enzymes. Polysaccharides, like guar gum, pectin, and chitosan, are frequently used as discharge rate-regulating ingredients in dosage forms intended for the colon. Although these polysaccharides have been shown to be resistant to intestinal and gastric enzymes, anaerobic bacteria in the colon digest them. Additionally, it is well recognized that medicines can be bio transformed by intestinal enzymes. When medications are broken down by the colonic enzymes, metabolites that are either pharmacologically active, inactive, or occasionally even dangerous might be produced. One popular "prodrugs" strategy for colon-specific delivery systems for drugs is the creation of a medicinally potent metabolite by drug metabolism in the colon (Ajaya Kumar *et al.*, 2004).

5.2.7 Formulation factors

Colic drug administration and uptake are influenced by formulation factors such as the dose, form of administration variables, and the physicochemical properties of the drugs. The amount of colonic fluid (1–44 ml) that is available for dissolution makes a medication's solubility and dosage essential to its colonic bioavailability. The highly efficient drug budesonide (dose: 9 mg) has excellent absorption in the colon and effectively treats ulcerative colitis, although possessing a lower solubility in water. Mesalamine has a substantially better solubility (3.64 mg/ml) than budesonide; however, the higher dose (4.8 g daily) of mesalamine becomes a rate-limiting factor for its absorption in the colon.

5.3 Conventional approach for achieving colonic delivery

5.3.1 Prodrugs

Prodrugs are inert drug molecules that, when broken down by digestive enzymes such those in the colon, produce the active component. The degree of this hydrolysis should be substantially greater in the colon than it is in the upper gastrointestinal tract in order to maximize medication distribution that is particular to the colon. Among the chemicals in this category, azo combines are among the most studied. Nevertheless, given that it depends on the drug molecule's groups of function, this approach is not highly adaptable. Kim et al. created a prodrug of metronidazole, which when injected into the rats' cecum, converted into the active medication, metronidazole (Chopade *et al.,* 2012). This prodrug did not undergo small intestine metabolism, in contrast to metronidazole, and its total absorption was likewise observed to be significantly lower than that of oral metronidazole. In a different investigation, Kim and colleagues synthesized a prodrug of metronidazole with a sulfate group. They demonstrated that the resulting solution stayed intact in the upper intestine but broke down when ratcecal secretions were present, releasing active metronidazole. Much less of the conjugated prodrug was broken down and incorporated in the small intestine following oral administration than the active medication, which resembles the first prodrug. precisely a result, very little entered the systemic circulation (Dhami *et al.,* 2018). In the context of colon-specific drug delivery, prodrugs can be designed to release the active drug primarily in the colon region. This is particularly useful for treating conditions like inflammatory bowel disease (IBD) or colon cancer.

Here are a few strategies for designing prodrugs for colon-specific drug delivery:

pH-Dependent prodrugs: The colon has a slightly alkaline pH, which is distinct from the more acidic environment in the stomach and the small intestine. Prodrugs can be designed to remain stable in the stomach and small intestine and then undergo cleavage in the colon due to the higher pH. For example, azo compounds are pH-sensitive prodrugs that can be designed to release the active drug in the colon (Christl *et al.,* 1997).

Bacterial enzyme-activated prodrugs: The colon is rich in various bacterial enzymes that can be used to trigger the release of the active drug from prodrugs. For instance, azoreductases and

glycosidases present in the colon can be used to cleave specific bonds in prodrugs, releasing the active compound.

Colon specific polymers: Drug delivery systems, such as microparticles or nanoparticles, can be designed with colon-specific polymers that degrade in the colon environment. These polymers can be used to encapsulate the active drug as prodrugs and release them selectively in the colon.

Time dependent prodrugs: Time-dependent prodrugs are designed to release the active drug after a specific period of time. This can be achieved by using coatings that degrade over time, ensuring that the prodrug reaches the colon intact before releasing the active compound.

Colonic Targeting Ligands: Prodrugs can be modified with ligands that specifically target receptors or transporters in the colon, allowing for selective uptake and activation of the prodrug in the colon cells. (Duga *et al*., 2018).

5.3.2 Colons specific biodegradable delivery systems

Pharmaceutical formulations intended to target the absorption of drugs in the colon, or lower gastrointestinal tract, are known as colon-specific biodegradable delivery systems. Inflammatory bowel disease (IBD), Crohn's disease, and colorectal cancer are among the ailments that these systems are mainly utilized to manage. They have a number of benefits, like as increased patient compliance, decreased systemic adverse effects, and improved medication efficacy. These are some important features of biodegradable methods of delivery tailored to the colon (Sandle, 1998):

Targeted drug delivery: These systems are designed to release the drug specifically in the colon region, ensuring that the active pharmaceutical ingredient (API) reaches its target site and exerts its therapeutic effect locally. This targeted delivery reduces systemic exposure and minimizes side effects associated with many drugs.

pH-dependent systems: One common approach to colon-specific drug delivery is to utilize pH-sensitive polymers or coatings. The colon has a distinct pH environment, which is slightly acidic (pH 6.0-7.4). pH-dependent systems are engineered to remain intact in the stomach and small intestine (pH around 1-4) but degrade or release the drug in the colon due to the higher pH (Schiller *et al*., 2005).

Time dependent systems: Another approach is to use time-dependent delivery systems. These rely on the transit time of food and drug formulations through the gastrointestinal tract. They release the drug after a certain amount of time has passed, ensuring that it reaches the colon before being released.

Microbial triggered systems: The colon contains a wide variety of microorganisms, particularly anaerobic bacteria, which can be leveraged for drug release. Microbial-triggered systems use specific polymers that are metabolized by these bacteria, leading to drug release in the colon.

Coatings and encapsulation: In some cases, biodegradable coatings or encapsulation techniques are used to protect the drug from early release. Once in the colon, these coatings break down, allowing the drug to be released (Shameem *et al.,* 2005).



Figure 3: Core tablet formulation for colon delivery

Figure 3 schematic representation of the cross section of the enteric coated colon-targeted drug delivery system (Glasier, 1993)

Polymeric matrices: Biodegradable polymeric matrices can be employed to encapsulate drugs. These matrices gradually degrade and release the drug over time, allowing for controlled and targeted delivery.

Advantages:

- Reduced systemic side effects: By targeting the colon, these delivery systems can minimize side effects often seen with oral medications.
- Enhanced drug bioavailability: Ensures a higher drug concentration at the target site, leading to improved therapeutic outcomes.
- Improved patient compliance: Colon-specific drug delivery systems may require less frequent dosing, which can improve patient adherence to treatment regimens.

Applications: These systems are primarily used in the treatment of colon-related diseases and conditions, such as IBD, Crohn's disease, colorectal cancer, and irritable bowel syndrome. They can also be used for the delivery of specific drugs that need to be targeted to the colon for various reasons (Pijper and Discombe, 2019).

In conclusion, colon-specific biodegradable delivery systems offer a promising approach to enhance the therapeutic efficacy of drugs in the treatment of colon-related diseases while minimizing systemic side effects. These systems utilize various strategies, such as pH-dependent, time-dependent, and microbial-triggered mechanisms, to achieve targeted drug release in the colon (Johns and Eyzaguirre, 2006).

5.3.3 Matrix based systems

Matrix-based systems for colonic drug delivery are designed to release drugs specifically in the colon, the lower part of the gastrointestinal tract. These systems are particularly useful for drugs that are either degraded or absorbed in the upper gastrointestinal tract and need to be targeted to the colon for optimal therapeutic effect. Colonic drug delivery can be beneficial for the treatment of various conditions such as inflammatory bowel disease, colorectal cancer, and certain infections. Matrix-based systems work by encapsulating the drug within a matrix or a delivery system that is resistant to the acidic and enzymatic environment of the stomach and small intestine but can release the drug in the colon where pH conditions are milder and drug absorption is more favorable (Pijper and Discombe, 2022).

5.3.4 Time release system

A time-release system for colonic drug delivery, often referred to as a colonic drug delivery system, is designed to release medication or therapeutic agents in a controlled manner specifically in the colon, which is the lower part of the gastrointestinal tract. This type of drug delivery system is useful for treating various gastrointestinal diseases, such as Crohn's disease, ulcerative colitis, and irritable bowel syndrome, as well as for delivering drugs that need to bypass the stomach and upper intestine to minimize their exposure to gastric acid or digestive enzymes (Evans *et al.*, 2019).

Several approaches and technologies can be employed to achieve time-controlled drug release in the colon:

Enteric coating: Enteric coatings are designed to protect the drug from being released in the stomach and upper intestines, allowing the drug to pass through to the colon before it starts to dissolve. This can be achieved through pH-dependent or enzyme-dependent coatings.

Pressure controlled systems: These systems are designed to release the drug in response to the pressure in the colon, which can vary with factors like food intake or gastrointestinal motility.



Figure 4: OROS-CT colon delivery

Figure 4 schematic representation of the cross section of the OROS-CT colon targeted drug delivery system (Patil, 2014)

Polymer-based systems: Polymers can be used to encapsulate drugs and control their release in the colon. The choice of polymer and its properties can be adjusted to achieve the desired drug release profile (Viswanathani *et al*., 2002).

It's essential to choose the appropriate method for your specific drug and therapeutic goals. The selection depends on factors like the drug's properties, the desired release profile, and patient considerations. The development of these systems can be quite complex and may require collaboration between pharmaceutical scientists, chemists, and engineers. Regulatory approval is also necessary to ensure the safety and efficacy of these drug delivery systems (Yadav et al., 2014).

5.3.5 Bio adhesive systems

Bio adhesive systems for colonic drug delivery are designed to enhance the targeted delivery of drugs to the colon, which can be particularly useful for the treatment of diseases such as inflammatory bowel disease (IBD), colonic cancer, and infections. These systems utilize bio adhesive polymers or formulations that can adhere to the colonic mucosa, allowing for controlled and sustained release of drugs. Here's an overview of bioadhesive systems for colonic drug delivery (Zreen *et al.*, 2022): The development of these systems can be quite complex and may require collaboration between pharmaceutical scientists, chemists, and engineers. Regulatory approval is also necessary to ensure the safety and efficacy of these drug delivery systems.

Bioadhesive polymers:

Hydrogels: Hydrogels are commonly used in colonic drug delivery systems due to their bioadhesive properties. They can adhere to the colonic mucosa and provide sustained drug release.

Chitosan: Chitosan is a natural polymer derived from chitin. It has mucoadhesive properties and can be used in various drug delivery systems for the colon.

Pectin: Pectin is another natural polymer with good bioadhesive properties. It forms a gel when exposed to the colonic environment, allowing for prolonged drug release.

Carbopol: Carbopol is a synthetic polymer that can be used to create bioadhesive drug delivery systems for the colon.

Mechanisms of adhesion:

Bioadhesion can occur through various mechanisms, including electrostatic interactions, hydrogen bonding, and van der Waals forces. The choice of polymer and formulation depends on the specific mechanism needed for drug adhesion (Ullah *et al*., 2010).

5.4 Limitation of colonic drug delivery system

Colonic drug delivery systems, also known as colon-specific drug delivery systems, are designed to release medications specifically in the colon. They offer several advantages in terms of targeting and treating conditions such as inflammatory bowel disease, Crohn's disease, and colon cancer. However, there are some drawbacks associated with these systems:

Variable transit times: The colon is located at the end of the gastrointestinal tract, and its transit time can vary significantly from person to person. This variability can make it challenging to predict when the drug will be released, potentially leading to inconsistent therapeutic effects.

Lack of precision: While colonic drug delivery systems aim to target the colon, there is no guarantee that the drug will only act in this specific region. Some drug may still be absorbed or released in other parts of the gastrointestinal tract, potentially leading to unwanted side effects or reduced efficacy (Beloqui *et al.,* 2015).

Limited applicability: Colonic drug delivery systems are primarily useful for conditions affecting the colon or lower gastrointestinal tract. They may not be suitable for treating conditions that affect other parts of the body, as the drug may not reach its intended target.

Patient variability: Individual variations in colon physiology and transit times can affect the drug's release and absorption. Factors such as age, diet, and underlying medical conditions can influence the effectiveness of colonic drug delivery systems (Duga, 2018).

Risk of dose dumping: If the drug delivery system is not designed properly, there is a risk of dose dumping, where a large amount of the drug is released suddenly in the colon. This can lead to side effects or toxicity.

Formulation challenges: Developing an effective colonic drug delivery system can be complex and may require special coatings, formulations, or technologies to ensure that the drug reaches the colon intact. Formulation challenges can increase the cost and complexity of drug development.

Limited commercial availability: Not all drugs are available in colonic delivery formulations, limiting treatment options for certain conditions.

Patient compliance: Patient compliance is essential in ensuring the effectiveness of colonic drug delivery systems. Patients must follow dosing instructions carefully, which can be challenging for some individuals.

In summary, while colonic drug delivery systems offer a targeted approach for treating specific gastrointestinal conditions, they come with limitations related to variability in transit times, precision, patient variability, and formulation challenges. These drawbacks need to be considered when developing and using such systems.

Table 1: Colon targeting diseases, drugs and sites.

Target sites	Disease conditions	Drug and active agents
Topical action	Inflammatory Bowel Diseases, Irritable bowel disease and Crohn's disease.	Hydrocortisone, Budenoside, Prednisolone, Sulfaselazine, Olsalazine, Mesalazine, Balsalazide (Verma P, 2012).
Local action	Chronic pancreatitis Pancreatactomy, Cystic fibrosis, Colorectal cancer.	Digestive enzyme supplements 5-Flourouracil (Vandamme, 2002)
Systemic action	To prevent gastric irritation To prevent first pass metabolism of orally ingested drugs Oral delivery of peptides Oral delivery of vaccines	NSAIDS Steroids Insulin Typhoid (Ravisankar P, 2015)

Table 1 represent that different type of colon targeting drug and their target site (Mahar, 2014)

Chapter six

Conclusion

6. Conclusion

The field of colon-specific drug delivery systems (CDDS) represents a promising avenue for addressing the challenges associated with the treatment of various gastrointestinal diseases and improving the therapeutic efficacy of drugs. This comprehensive review has provided insights into the various strategies and technologies employed in CDDS, including pH-sensitive, time-controlled, and microbially triggered systems, among others. The advantages of CDDS, such as reduced systemic side effects, enhanced drug bioavailability, and improved patient compliance, underscore its potential significance in clinical applications.

However, it is crucial to acknowledge that the development and optimization of CDDS are not without challenges, including formulation complexities, regulatory considerations, and patient-specific factors. Future research in this area should focus on overcoming these hurdles, as well as exploring innovative approaches, such as nanotechnology and personalized medicine, to further advance the field. Colon-specific drug delivery systems offer a promising solution to enhance the precision and efficacy of drug therapies for colonic disorders, and their continued development holds great potential for improving patient outcomes and quality of life. As research and technology continue to evolve, the realization of safe and effective CDDS in clinical practice may be within reach, offering new hope for patients with a variety of colon-related health issues.

Chapter seven

Reference

7. Reference

Agarwal T, Narayana SNGH, Pal K, Pramanik K, Giri S, Banerjee I. Fermentation in the Human Large Intestine and the Available Substrates. International Journal of Biological Macromolecules. *2015:* 75, **409–17.**

Ahilip AK, Dabas S, Pathak K. Optimized Prodrug pproach: A Means for Achieving Enhanced Anti-Inflammatory Potential in Experimentally Induced Colitis. Journal of Drug Targeting *2009*: 17[3], **235-241**

Aronica, M., Foss, E., Diamond, J., Santana, F., Darley, J., Dowd, P. F., Coleman, C. M., & Ferreira, D. Controlled Drug Delivery: Concepts and Advances. Journal of Natural Products; *2014:* 77[5], **1140–1149.**

Azadbakhta, M., Safapour, S., Ahmadi, A., Ghasemi, M., & Shokrzadeh, Pharmaceutical Approaches to Colon Targeted Drug Delivery Systems. International Journal of Biological Macromolecules. *2010:* 2[2], **10–16.**

Azad, M., Safapour, S., Ahmadi, A., Ghasemi, M., & Shokrzadeh, Pharmaceutical Tactics to Colon Targeted Drug Delivery Systems. Journal of Natural Products. *2011:* 2[2], **10–16.**

Bhattacharya, B., Laskar, S., & Banerjee, Perspectives on Colonic Drug Delivery International Journal of Biological Macromolecules. *2004:*15[2], **109–111**.

Barik, A., Bhattacharya, B., Laskar, S., & Banerjee, Perceptions on Colonic Drug Delivery. Journal of Drug Targeting. *2006:*15[2], **105–111**.

Beckert T, Petereit HU, Dressman J, Rudolph M. Multi-particulate form of Medicament, Comprising at Least two Differently Coated forms of Pellet. Journal of Drug Targeting. *2005:* 10[2], **263–709**

Belofsky, G., Aronica, M., Foss, E., Diamond, J., Santana, F., Darley, J., Dowd, P. F., Coleman, C. M., & Ferreira, D. Controlled Drug Delivery: Concepts and Advances. Journal of Natural Products; *2014:* 77[5], **1140–1149.**

Beloqui A, Coco R, Memvanga PB, Ucakar B, des Rieux A, Preat V. pH-sensitive Nanoparticles for Colonic Delivery. International Journal of Biological Macromolecules. *2014:* 473[1–2], **203–12.**

Bharadwaj, K. K., Rabha, B., Pati, S., Choudhury, B. K., Sarkar, T., Gogoi, S. K., Kakati, N., Baishya, D., Kari, Z. A., & Edinur, H. A. Colonic Drug Absorption and Metabolism. Journal of Natural Products. *2021:* 11[8], **23-34.**

Chandra, S., Chatterjee, P., Dey, P., & Bhattacharya, S. Oral Delayed Release System for Colonic Specific Drug Delivery. Pharmacognosy Journal; *2012:* 4[29], **47–49.**

Chatterjee, P., Dey, P., & Bhattacharya, S. Oral Delayed Release System for Colonic Specific Drug Delivery. Pharmacognosy Journal; *2012:* 4[29], **47–49.**

Chauhan A, Mittu B, Chauhan P. Analytical method development and validation: a concise review. Scandinavian Journal of Gastroenterology. *2015:* **1-6.**

Chopade, A. R., Somade, P. M., & Sayyad, F. J. Membrane stabilizing activity and protein denaturation: A possible mechanism of action for the anti-inflammatory activity of Phyllanthus amarus. Journal of Krishna Institute of Medical Sciences University; *2012*: 1[1], **67–72.**

Christl SU, Scheppach W. Metabolic consequences of total colectomy. Scandinavian Journal of Gastroenterology. *2019*: 222, **20–4.**

Coco R, Memvanga PB, Ucakar B, des Rieux A, Preat V. pH-sensitive Nanoparticles for Colonic Delivery. International Journal of Biological Macromolecules. *2014:* 473[1–2], **203–12.**

Coupe AJ, Davis SS, Wilding IR. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm Res. 2018: 8[3], **360–4.**

Dabas S, Pathak K. Optimized Prodrug pproach: A Means for Achieving Enhanced Anti-Inflammatory Potential in Experimentally Induced Colitis. Journal of Drug Targeting *2009*: 17[3], **235-241**

Deshmukh R, Jha A. Role of natural polymers in the development of multiparticulate systems for colon drug targeting. Systematic Reviews in Pharmacy. *2010:* 1[1], **79–85.**

Dhami, A., Palariya, D., Singh, A., Kumar, R., Prakash, O., Kumar, R., Ravendra Kumar, C., & Pant, A. Chemical composition, antioxidant, in vitro anti-inflammatory and antibacterial activity of seeds essential oil of Zanthoxylum armatum DC. Collected from two different altitudes of Kumaun region, Uttarakhand. ~ 363 ~ International Journal of Chemical Studies; *2018*: 6[6], **363–370.**

Dorai, A. A. Wound care with traditional, complementary and alternative medicine. Indian Journal of Plastic Surgery; *2012:* 45[2], **418–424.**

Dressman J, Rudolph M. Multi-particulate form of Medicament, Comprising at Least two Differently Coated forms of Pellet. Journal of Drug Targeting. *2005:* 10[2], **263–709**

Dressman JB, Berardi RR, Dermentzoglou LC, Russell TL, Schmaltz SP, Barnett JL, et al. Upper gastrointestinal (GI) Ph in young, healthy men and women. Pharm Res. *2017:* 7[7], **756–61.**

Duga, A. Research Article Research Article. Archives of Anesthesiology and Critical Care; *2018:* 4[4], **527–534**.

Foss, E., Diamond, J., Santana, F., Darley, J., Dowd, P. F., Coleman, C. M., & Ferreira, D. Controlled Drug Delivery: Concepts and Advances. Journal of Natural Products; *2014:* 77[5], **1140–1149.**

Francis, S. In vivo Efficacy of Diospyros abyssinica Leaf 80 % Methanolic Extract from Tooro Botanical Gardens on Wounds using Mice EURASIAN EXPERIMENT JOURNAL OF MEDICINE AND MEDICAL SCIENCES (EEJMMS) ISSN : 2992- 4103 © EEJMMS Publications In vivo Efficacy of Dio; *2023:* 3[7] **119-123.**

Halim, A. El, Mohamed, A., Hafeez, Habeeb, R., & Azer, A. Taxonomic revision of Ebenaceae in Egypt. Current Science International: *2014:* 3[4], **414–415.**

Hameed, A., Kiran, S., Farooq, T., & Zaroog, M. S. A Comparative Study of Diospyros malabarica (Gaub) Extracts in Various Polarity-Dependent Solvents for Evaluation of Phytoconstituents and Biological Activities. BioMed Research; *2022*: 29[2], **109-115.**

Hossain, M. A. (2018). Green Dyeing On Cotton Fabric Demodulated From Diospyros Malabarica and Camellia Sinensis with Green Mordanting Agent. Latest Trends in Textile and Fashion Designing; *2018:* 2[2], **152–159.**

Ikram, M., Beshbishy, A. M., Kifayatullah, M., Olukanni, A., Zahoor, M., Naeem, M., Amin, M., Shah, M., Abdelaziz, A. S., Ullah, R., Mothana, R. A., Siddiqui, N. A., & Batiha, G. E. S. Chemotherapeutic potential of Carthamus oxycantha root extract as antidiarrheal and in vitro antibacterial activities. Antibiotics; *2020:* 9[5], **78-90.**

Iqbal, E., Salim, K. A., & Lim, L. B. L. Phytochemical screening, total phenolics and antioxidant activities of bark and leaf extracts of Goniothalamus velutinus (Airy Shaw) from Brunei Darussalam. Journal of King Saud University - Science; *2015:* 27[3], **224–232.**

Jatto E, Okhamafe AO. An overview of pharmaceutical validation and process controls in drug development. Trop J Pharm Res *2002:* 1[11], **5-22**.

Johns, T., & Eyzaguirre, P. B. Linking biodiversity, diet and health in policy and practice. Proceedings of the Nutrition Society; *2006:* 65[2], **182–189.**

Joshua, M. T., Wachuku, E. O., Boisa, N., & Nduka, N. Evaluation of Antidiabetic Potentials of Morus mesozygia Linn. Stapf., Leaf Extracts in Streptozotocin-Induced Diabetic Rats. Journal of Complementary and Alternative Medical Research; *2020:* 1[3], **23–32.**

Kaushik, V., Saini, V., Pandurangan, A., Lal Khosa, R., & Parcha, V. A review of Phytochemical and biological studies of Diospyros malabarica Anti-diabetics herbal View project A review of Phytochemical and biological studies of Diospyros malabarica. International Journal of Pharmaceutical Sciences Letters; *2013:* 2[6], **167–169**.

Kavatagimath, S. A., & Jalalpure, S. S. Screening of ethanolic extract of diospyros malabarica desr. Bark for anti-diabetic and antioxidant potential. Indian Journal of Pharmaceutical Education and Research; *2016:* 50[1], **179–189.**

Kedare, S. B., & Singh, R. P. Genesis and development of DPPH method of antioxidant assay. Journal of Food Science and Technology: *2011:* 48[4], **412–422.**

Kim H, Lee Y, Yoo H, Kim J, Kong H, Yoon JH, et al. Synthesis and evaluation of sulfate conjugated metronidazole as a colon-specific prodrug of metronidazole. J Drug Target. *2012:* 20[3], **255–63.**

Klančnik, A., Piskernik, S., Jeršek, B., & Možina, S. S. Evaluation of diffusion and dilution methods to determine the antibacterial activity of plant extracts. Journal of Microbiological Methods; *2010*: 81[2], **121–126.**

Laskar, S., & Banerjee, Perspectives on Colonic Drug Delivery. Journal of Drug Targeting. *2004:*15[2], **109–111**.

Mathew, A., Madhu, C. D., & Philip, S. Antioxidant activity of some common medicinal plants. International Journal of Pharmaceutical and Clinical Research; *2013:* 5[2], **43–46.**

Memvanga PB, Ucakar B, des Rieux A, Preat V. pH-sensitive Nanoparticles for Colonic Delivery. International Journal of Biological Macromolecules. *2014:* 473[1–2], **203–12.**

Miah, M. M., Das, P., Ibrahim, Y., Shajib, M. S., & Rashid, M. A. In vitro antioxidant, antimicrobial, membrane stabilization and thrombolytic activities of Dioscorea hispida Dennst. European Journal of Integrative Medicine, *2019*: 19[8], **121–127.**

Modasiya MK, Patel VM. Design of colon specific drug delivery using sodium alginate and HPMC. J Pharm Res. *2012*: 5[4], **2253–8.**

Mondal, S. K., Chakraborty, G., Bhaumik, U. K., Gupta, M., & Mazumder, U. K. Antidiabetic activity of Diospyros malabarica Kostel bark: a preliminary investigation for possible mode of action. Oriental Pharmacy and Experimental Medicine; *2008:* 8[3], **236–242.**

Mondal, S. K., Chakraborty, G., Gupta, M., & Mazumder, U. K. In vitro antioxidant activity of Diospyros malabarica Kostel bark. Indian Journal of Experimental Biology, *2006:* 44[1], **39–44.**

Moniruzzaman, M., Kuddus, M. R., Chowdhury, A. S., & Rashid, M. A. Antioxidant, Antimicrobial, Anti-diarrheal and Analgesic Activities of Diospyros malabarica (Desr.) Kostel. Bangladesh Pharmaceutical Journal; *2019:* 22[1], **27–33.**

Narayana SNGH, Pal K, Pramanik K, Giri S, Banerjee I. Fermentation in the Human Large Intestine and the Available Substrates. International Journal of Biological Macromolecules. *2015:* 75, **409–17.**

Narayana SNGH, Pal K, Pramanik K, Giri S, Banerjee I. Fermentation in the Human Large Intestine and the Available Substrates. International Journal of Biological Macromolecules. *2015:* 75, **409–17.**

Newman, D. J., & Cragg, G. M. Natural Products as Sources of New Drugs from 1981 to 2014. Journal of Natural Products; *2016:* 79[3], **629–661.**

Panda, S. K., Mohanta, Y. K., Padhi, L., & Luyten, W. Antimicrobial activity of select edible plants from Odisha, India against food-borne pathogens. Lwt; *2019:* 9[13], **113**.

Patel A, Dwivedi N, Kaurav N, Bashani S, Patel S, Sharma HS, et al. Chemical analysis of pharmaceuticals: a review. J Med Pharm Innov *2016:* 3, **4-7**.

Pathak K. Optimized Prodrug pproach: A Means for Achieving Enhanced Anti-Inflammatory Potential in Experimentally Induced Colitis. Journal of Drug Targeting *2009*: 17[3], **235-241**

Pathuri R, Muthukumaran M, Krishnamoorthy B, Nishat A. A review on analytical method development and validation of the pharmaceutical technology. Curr Pharm Res *2013*: 3[8], **55-70**.

Pati, S., Choudhury, B. K., Sarkar, T., Gogoi, S. K., Kakati, N., Baishya, D., Kari, Z. A., & Edinur, H. A. Colonic Drug Absorption and Metabolism. Journal of Natural Products. *2021:* 11[8], **23-34.**

Patil R, Deshmukh T, Patil V, Khandelwal K. Review on analytical method development and validation. Res Rev J Pharm Anal *2014:* 3, **1-10.**

Rabha, B., Pati, S., Choudhury, B. K., Sarkar, T., Gogoi, S. K., Kakati, N., Baishya, D., Kari, Z. A., & Edinur, H. A. Colonic Drug Absorption and Metabolism. Journal of Natural Products. *2021:* 11[8], **23-34.**

Ramaiah, M., Uma Rani, N. T., Harshitha, N. H., Priya, P. S., & Sruthi, T. Investigation of Invitro Anthelmenthic Activity of Diospyros malabarica (Kostel Bark). International Journal of Pharmacognosy and Phytochemical Research; *2017:* 9[08], **1135–1137.**

Rode, M. S., Kalaskar, M. G., Gond, N. Y., & Surana, S. J. Evaluation of anti- diarrheal activity of diospyros malabarica bark extract. Bangladesh Journal of Pharmacology; *2013:* 8[1], **49–53.**

Safapour, S., Ahmadi, A., Ghasemi, M., & Shokrzadeh, Pharmaceutical Approaches to Colon Targeted Drug Delivery Systems. International Journal of Biological Macromolecules. *2010:* 2[2], **10–16.**

Sahar Javed, Sabi Rehman, Muzamil Zaman Khan, Anwar Khalid, Rida Qaseem, & Muhammad Humayun. Evaluation of in vitro pharmacological activities of Diospyros malabarica kostel fruit. Journal of Contemporary Pharmacy; *2020:* 4[1], **5–9.**

Shaira, H. A., Shomudro, H. K., & Chowdhury, S. A. In-vitro and In-vivo Pharmacological Evaluation of Persicaria lapathifolia Available in Bangladesh. Journal of Scientific Research and Reports; *2023:* 29[3], **12–26.**

Shomudro, H. K. Pharmacological Investigation of in- vitro Anti-inflammatory, Antimicrobial, Thrombolytic, Cytotoxic and In vivo Analgesic Activities of Ethanolic Leaf Extract of Diospyros malabarica. August; *2023:* 7[2], **17-25.**

Shomudro, H. K., Shaira, H. A., & Afreen, S. Evaluation of in vitro antioxidant , anti- bacterial , cytotoxic and in vivo analgesic and neuro- pharmacological investigation of alysicarpus vaginalis available in Bangladesh: *2023*:12[1], **316–323.**

Shrestha, R., Dawadi, P., Bhusal, S., & Bhatt, L. R. Nutritional value and antioxidant properties of Diospyros malabarica (Desr.) Kostel., fruit from midhills of western Nepal. Nepal Journal of Science and Technology; *2021:* 20[1], **113–125.**

Shubhra, R. D., Polash, S. A., Hossain, M. M., Hamza, A., Tushar, M. M. H., Saha, T., Hasan, M. A., Sikder, M. M., Alam, N., Islam, Z., Hossain, M. S., & Sarker, S. R. (2021). Investigation of the Antimicrobial Activity and <i>in Vivo </i> Cytotoxicity of <i>Diospyros malabarica </i> (Desr.) Kostel. Fruit Extracts. Natural Science; *2021:* 13[08], **331–351.**

Sosnová, M., & Klimešová, J. Life-history variation in the short-lived herb Rorippa palustris: The role of carbon storage. Acta Oecologica; *2009:* 35[5], **691–697**.

Tairin, I., Abhijit, D., Kumar, B. S., Palash, K., Shafiul, I., & Mohammad, M. S. Evaluation of membrane stabilizing, anthelmintic, antioxidant activity with phytochemical screening of methanolic extract of Neolamarckia cadamba fruits. Journal of Medicinal Plants Research; *2015:* 9[5], **151–158.**

Ugbogu, O., Olowokudejo, J., & Ogundipe, O. Leaf epidermal morphology of Diospyros (Ebenaceae) in Nigeria. Phytologia Balcanica; *2016:* 22[3], **377–385.**

Ullah, R., Hussain, Z., Iqbal, Z., Hussain, J., Khan, F. U., Khan, N., Muhammad, Z., Ayaz, S., Ahmad, S., Rehman, N. U., & Hussain, I. Traditional uses of medicinal plants in Darra Adam Khel NWFP Pakistan. Journal of Medicinal Plants Research, *2010*: 4[17], **1815–1821.**

Usman, H., Victor, V., & Waziri, I. Qualitative Phytochemical Screening and in Vitro Antimicrobial Activities of Solanum Americanum Mill. Journal of Engineering, Technology, and Environment; *2018:*14[1], **104–110.**

Valgas, C., De Souza, S. M., Smânia, E. F. A., & Smânia, A. Screening methods to determine antibacterial activity of natural products. Brazilian Journal of Microbiology,; *2007:* 27[4], **7-14.**

Viswanathani, M. B., Maridass, M., Thangadurai, D., & Ramesh, N. Chemical constituents of the fruit essential oil of Diospyros malabarica (Desr.) Kostel (Ebenaceae). Acta Pharmaceutica; *2002:* 52[3], **207–211.**

Yadav, A. K., Temjenmongla, & Deori, K. In-vitro and In-vivo Anthelmintic Effects of Gynura angulosa (Compositae) Leaf Extract on Hymenolepis diminuta, a Zoonotic Tapeworm. Journal of Biologically Active Products from Nature; *2014:* 4[3], **171– 178.**

Ye L, Hong Z. Budesonide-loaded guar gum microspheres for colon delivery: preparation, characterization and in vitro/in vivo evaluation. Int J Mol Sci. *2015:* 16[2], **2693–704.**